UK Market

HUTCHMED Stock Analysis & Ratings

GB:0J7G Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was HUTCHMED’s price range in the past 12 months?
HUTCHMED lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is HUTCHMED’s market cap?
    HUTCHMED’s market cap is $1.77B.
      What is HUTCHMED’s price target?
      The average price target for HUTCHMED is $19.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $22.00 ,the lowest forecast is $17.00. The average price target represents 92.09% Increase from the current price of $10.24.
        What do analysts say about HUTCHMED?
        HUTCHMED’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is HUTCHMED’s upcoming earnings report date?
          HUTCHMED’s upcoming earnings report date is Aug 03, 2022 which is in 77 days.
            How were HUTCHMED’s earnings last quarter?
            HUTCHMED released its earnings results on Mar 03, 2022. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.084 by -$0.206.
              Is HUTCHMED overvalued?
              According to Wall Street analysts HUTCHMED’s price is currently Undervalued.
                Does HUTCHMED pay dividends?
                HUTCHMED does not currently pay dividends.
                What is HUTCHMED’s EPS estimate?
                HUTCHMED’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does HUTCHMED have?
                HUTCHMED has 172,910,000 shares outstanding.
                  What happened to HUTCHMED’s price movement after its last earnings report?
                  HUTCHMED reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.084. Following the earnings report the stock price went same N/A.
                    Which hedge fund is a major shareholder of HUTCHMED?
                    Among the largest hedge funds holding HUTCHMED’s share is Sands Capital Management LLC. It holds HUTCHMED’s shares valued at 79M.


                      HUTCHMED Stock Analysis

                      The HUTCHMED stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description


                      Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.

                      Similar Stocks
                      Price & Change

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis